Combining Lisinopril and Verapamil for Hypertension Management

Introduction to Combination Therapy

The American Heart Association recommends combining lisinopril and verapamil as an effective, evidence-based combination for hypertension management, particularly when monotherapy fails to achieve blood pressure control 1, 2

The INVEST trial demonstrated equivalent cardiovascular outcomes when comparing verapamil-based regimens to beta-blocker-based regimens in 22,000 hypertensive patients with chronic coronary artery disease, with no difference in cardiovascular death, MI, or coronary revascularization 1, 2
ACE inhibitors were frequently added to verapamil therapy in major trials—63% of verapamil patients in INVEST required addition of the ACE inhibitor trandolapril by 24 months, demonstrating this is a commonly used and necessary combination strategy 1, 2

Verapamil reduces peripheral vascular resistance, slows heart rate, and decreases AV nodal conduction while providing coronary vasodilation 1, 2
Lisinopril blocks the renin-angiotensin system, prevents ventricular remodeling, and provides cardioprotection and renoprotection 3

The American College of Cardiology recommends avoiding verapamil in patients with heart failure with reduced ejection fraction or LV systolic dysfunction, as verapamil should never be used in these patients 1, 3, 4
The European Society of Cardiology advises monitoring heart rate and PR interval due to verapamil's negative chronotropic effects, which can cause bradycardia and prolong AV conduction 3
The American Heart Association suggests monitoring blood pressure, as both agents lower BP, and monitoring for hypotension, particularly when initiating or uptitrating doses 3
The National Kidney Foundation recommends monitoring renal function and potassium, as ACE inhibitors can cause hyperkalemia and renal dysfunction, especially when combined with other BP-lowering agents 3

The American Diabetes Association recommends titrating to achieve target BP <130/80 mmHg in patients with diabetes, chronic kidney disease, or CAD 5

The American College of Cardiology advises considering alternative combinations, such as a dihydropyridine CCB, in patients with heart failure with reduced ejection fraction, as dihydropyridines lack significant negative inotropic effects 1, 3, 2
The European Society of Cardiology recommends avoiding this combination in patients also on a beta-blocker, as long-acting dihydropyridines are preferred over nondihydropyridines to avoid excessive bradycardia or heart block 1, 2, 5

The American Heart Association recommends an ACE inhibitor plus dihydropyridine CCB (e.g., lisinopril + amlodipine) as a preferred combination with proven cardiovascular benefit 4, 5
The European Society of Cardiology suggests an ACE inhibitor plus thiazide diuretic as another well-established effective combination 4